Stock Events

Stock Events

Adocia 

€4.78
0
+€0.29+6.36% Friday 18:46

Statistics

Day High
4.78
Day Low
4.64
52W High
10.66
52W Low
3.21
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

24FebExpected
Q4 2025
-0.57
-0.4
-0.22
-0.05
Expected EPS
-0.0498579495
Actual EPS
-0.5683806242999999

People Also Follow

This list is based on the watchlists of people on Stock Events who follow A89.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap164.13B
Novo Nordisk is a leading global healthcare company that focuses on diabetes care, where Adocia also has significant investments, making them direct competitors in the diabetes treatment market.
Sanofi
SNY
Mkt Cap116.63B
Sanofi is involved in diabetes and cardiovascular diseases treatment research, directly competing with Adocia's diabetes management products.
Lilly(Eli) &
LLY
Mkt Cap837.36B
Eli Lilly is a major player in the diabetes care market, developing insulin and other diabetes treatments that compete with Adocia's product offerings.
Merck
MRK
Mkt Cap298.84B
Merck & Co. focuses on diabetes treatment through its drug portfolio, positioning it as a competitor to Adocia in the diabetes care sector.
Astrazeneca
AZN
Mkt Cap315.47B
AstraZeneca operates in various therapeutic areas, including diabetes, where its products compete with Adocia's diabetes treatments.
Bristol-Myers Squibb
BMY
Mkt Cap121.69B
Bristol-Myers Squibb has a presence in the diabetes treatment market, making it a competitor to Adocia with its range of diabetes care products.
Novartis
NVS
Mkt Cap297.32B
Novartis AG, through its research and development in diabetes and metabolic diseases, competes with Adocia in the diabetes treatment market.
Pfizer
PFE
Mkt Cap161.09B
Pfizer is involved in the discovery, development, and manufacture of healthcare products including treatments for diabetes, competing with Adocia.
Tandem Diabetes Care
TNDM
Mkt Cap1.27B
Tandem Diabetes Care designs, develops, and commercializes products for people with insulin-dependent diabetes, directly competing with Adocia's insulin management solutions.
Insulet
PODD
Mkt Cap14.38B
Insulet Corporation, through its Omnipod Insulin Management System, competes in the insulin delivery market, directly challenging Adocia's diabetes treatment solutions.

About

Adocia SA, a clinical-stage biotechnology company, researches and develops therapeutic solutions for diabetes and obesity. Its proprietary BioChaperone technological platform provides molecular delivery of therapeutic proteins. The company provides BioChaperone Lispro U100 and U200, which are ultra-rapid formulations based on rapid prandial insulin lispro; BioChaperone Combo, a combination of acting insulin glargine and rapid-acting insulin lispro; and BioChaperone LisPram, a combination of pramlintide and lispro, as well as M1Pram, a combination of insulin M1 and pramlintide. Its preclinical pipeline includes products for the treatment of diabetes and obesity, including AdoShell Islets, an implant containing islets of Langerhans; AdOral Sema, an oral delivery of semaglutide; and AdoGel Sema for the long-acting drug delivery of semaglutide. The company has a strategic alliance with Tonghua Dongbao Pharmaceutical Co., Ltd. to develop and commercialize BioChaperone Lispro in China and other Asian and Middle Eastern territories. Adocia SA was incorporated in 2005 and is headquartered in Lyon, France.
Show more...
CEO
Mr. Olivier Soula M.B.A., Ph.D.
Employees
77
Country
France
ISIN
FR0011184241

Listings

PA
FR
ADOBS.PA
STU
DE
A89.STU
PA
FR
ADOC.PA
F
DE
A89.F

0 Comments

Share your thoughts

FAQ

What is Adocia stock price today?▼
The current price of A89.STU is €4.78 EUR — it has increased by +6.36% in the past 24 hours. Watch Adocia stock price performance more closely on the chart.
What is Adocia stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Adocia stocks are traded under the ticker A89.STU.
Is Adocia stock price growing?▼
A89.STU stock has risen by +3.28% compared to the previous week, the month change is a -23% fall, over the last year Adocia has showed a +42.96% increase.
When is the next Adocia earnings date?▼
Adocia is going to release the next earnings report on September 24, 2026.
What were Adocia earnings last quarter?▼
A89.STU earnings for the last quarter are -0.57 EUR per share, whereas the estimation was -0.05 EUR resulting in a -1,040% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Adocia have?▼
As of April 11, 2026, the company has 77 employees.
In which sector is Adocia located?▼
Adocia operates in the Health & Wellness sector.
When did Adocia complete a stock split?▼
Adocia has not had any recent stock splits.
Where is Adocia headquartered?▼
Adocia is headquartered in Lyon, France.